Category: Parry
-
Tick-tock: Tocvan Ventures (TOC.C) quietly doing the work as it proves out an intriguing gold resource
When we first talked about Tocvan Ventures (TOC.C) back in June, it was selling for around $0.15 and nobody was really talking about it. In certain markets, hype is rewarded hard, but there’s something to be said for a deal in which what’s being said is the very essence of non-hype – and the stock…
-
Adults in the room alert: Kwesst (KWE.V) develops and sells video game future tech to modern day defense forces
If you’ve been paying attention over the last few years, you’ve seen a few nice runs for companies engaged in the security/military space. Patriot One (PAT.C) has done nicely with tech to sniff out security threats at crowded points of access. CAE (CAE.T) is a multi-billion dollar company working in the military sim space. Draganfly…
-
Bio-tech without the dice roll: Aequus Pharmaceuticals (AQS.V) building a solid, multi-pronged revenue earner
For the last several years, a lot of stories I’ve written on this site have been about promise. The promise of something better, cheaper, with more upside, with less downside. Promise that a team will do more, or do better, or do something – anything. Promise that, if the planets align, something big will come.…
-
Desert Mountain Energy (DME.V) wanted some money, the markets went all ‘No, take more! Take it all!’
Not so long ago, one of our sales guys called Desert Mountain Energy (DME.V) and said, ‘yo desert bros, we like helium, you got helium, let’s work together.’ DME politely face-palmed. ‘We don’t really have a lot of money,’ they said. ‘We’re transitioning.’ Then their stock ran from $0.70 to $1.70. Now they’ve got dollars.…
-
Plus Products (PLUS.C) 71% costs turnaround shows legitimacy in management, anchors growth
Esteemed California cannabis gummies maker Plus Products (PLUS.C) issued quarterly financials Thursday showing a substantial turnaround as their Nevada and national CBD growth plans take hold. After a 10c per share loss in Q1, the company presented a mere 1c per share loss in Q2, with $4.3 million in revenue, despite COVID-driven slowdowns in Nevada.…
-
AMPD Ventures (AMPD.C): 52% jump on high performance computing provider validates CEO stance of ‘patience and focus’
When folks ask AMPD Ventures (AMPD.C) CEO Anthony Brown what his company does, he usually asks, “Have you seen the Spielberg movie, Ready Player One?” Most people say no. That’s a shame, because the movie is great, and it explains what AMPD is looking to achieve pretty well. AMPD wants to build The Oasis, a…
-
TGS E-Sports (TGS.V) lands on the CSE with plans to build global gaming stadium empire
E-sports stocks are, by and large, a silly thing right now, with a lot of folks bringing out deals that make little sense financially. As with the psychedelic space, the blockchain world, and the early days of the cannabis sector, most investors are less concerned about long term viability as they are not missing a…
-
Brigadier Gold (BRG.V) rises from slumber and downs six cups of coffee
If you’ve been in the public markets on the microcap side for any length of time, the bodies stack up on your portfolio after a while. You know the ones, the flops that flopped too quickly to get rid of and now clutter up your page with a value lower than the broker commission they…
-
Revive Therapeutics (RVV.C) blasts off, up 68% after FDA Phase 3 COVID-19 approval
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3 clinical trials on the use of its Bucillamine medication as a potential treatment for patients with mild to moderate COVID-19. The U.S. Food and Drug Administration (FDA) has approved Revive…